Status:

RECRUITING

REDUCE LAP-HF III Corvia Protocol 1701

Lead Sponsor:

Corvia Medical

Conditions:

Heart Failure

Eligibility:

All Genders

40+ years

Brief Summary

This is a post market trial to be conducted at sites in Germany. The device has CE approval in the EU. The purpose of this observational registry is to collect post market data in consecutive patients...

Eligibility Criteria

Inclusion

  • This is a post market registry so no criteria requirements (only recommendations).

Exclusion

    Key Trial Info

    Start Date :

    July 12 2017

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ESTIMATED

    End Date :

    July 31 2028

    Estimated Enrollment :

    500 Patients enrolled

    Trial Details

    Trial ID

    NCT03191656

    Start Date

    July 12 2017

    End Date

    July 31 2028

    Last Update

    February 8 2024

    Active Locations (27)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 7 (27 locations)

    1

    Herzzentrum der Kerckhoff-Klinik

    Bad Nauheim, Germany

    2

    Herz- und Diabeteszentrum Nordrhein-Westfalen Klinik für Kardiologie

    Bad Oeynhausen, Germany

    3

    Segeberger Kliniken GmbH

    Bad Segeberg, Germany

    4

    Unfallkrankenhaus Berlin

    Berlin, Germany

    REDUCE LAP-HF III Corvia Protocol 1701 | DecenTrialz